Artes Biotechnology and Burnet Institute Join Forces to Develop a New Type of Malaria Vaccine
![](/46/pdcnewsitem/03/34/90/vgrUYfBTE0XRNIZ.jpg)
Artes Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI).
The project will use exciting novel technology developed at the Burnet Institute, by Deputy-Director, Associate Professor David Anderson and colleagues. Artes holds the international patent rights and adapted the platform to vaccine production (known as the Metavax platform).
Purified vaccine antigens (Pfs25 and Pfs230) will be produced as virus-like particles (VLPs, a type of nano-particle) for testing in laboratory studies. The VLPs will be taken up by immune cells to prime and prepare the immune system to fight malaria.
Although malaria is one of the world’s leading causes of illness and death there is currently no vaccine approved for use. More than 600,000 people die of malaria each year and it most severely affects young children and pregnant women.
Burnet Institute Co-Head of the Centre for Biomedical Research, Professor James Beeson says the challenges in developing an effective malaria vaccine are substantial.
“One of the challenges for malaria is how to best make vaccines to stimulate a strong and effective immune response and boost the immune system to fight malaria infections,” Professor Beeson said.
Arts Managing Director Dr Michael Piontek said the strong collaboration between Burnet and Artes is a great opportunity for developing new malaria vaccines: “In this new project, Burnet and ARTES will combine their expertise to develop and test a novel approach for producing malaria vaccines. We are excited about the recognition and support provided by MVI for this development work.”
Vaccines that interrupt the transmission of malaria aim to protect whole populations, toward the ultimate goal of malaria eradication.
The project will focus on strategies to produce vaccines that can block the transmission of malaria infection from mosquitoes to people, as part of a programme funded by MVI.
”At MVI, we think that transmission-blocking vaccines could play a significant role in the eventual eradication of malaria,” said Ashley J. Birkett, PhD, MVI Director. “We are therefore very pleased to be involved in this project, which uses an innovative approach to expressing transmission-blocking antigens.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance